Pyomyositis

Summary

Pyomyositis (MONDO:0019168) is a disease and 2 clinical trials. Top therapeutic interventions include cephalexin anhydrous and cefadroxil. A subtype of bacterial myositis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)
• Phenotypes (HPO): 12
• Clinical trials: 2

Clinical features

Signs & symptoms

Clinical features (HPO)

12 HPO clinical features (Orphanet curated; top 12 by frequency):

HPO ID	Term	Frequency
HP:0001482	Subcutaneous nodule	Very frequent (80-99%)
HP:0001945	Fever	Very frequent (80-99%)
HP:0003326	Myalgia	Very frequent (80-99%)
HP:0100614	Myositis	Very frequent (80-99%)
HP:0100838	Recurrent cutaneous abscess formation	Very frequent (80-99%)
HP:0001824	Weight loss	Frequent (30-79%)
HP:0001974	Leukocytosis	Frequent (30-79%)
HP:0002719	Recurrent infections	Frequent (30-79%)
HP:0100616	Testicular teratoma	Frequent (30-79%)
HP:0000083	Renal insufficiency	Occasional (5-29%)
HP:0001645	Sudden cardiac death	Occasional (5-29%)
HP:0100806	Sepsis	Occasional (5-29%)

Identifiers

Disease identifiers

Field	Value
Canonical name	pyomyositis
Mondo ID	MONDO:0019168
EFO	EFO:1001409
MeSH	D052880
Orphanet	764
DOID	DOID:876
ICD-11	856598467
NCIT	C128382
SNOMED CT	65110003
UMLS	C0041188
MedGen	52862
GARD	0004614
MedDRA	10037652
Is cancer (heuristic)	no

Also known as: myositis purulenta tropica · myositis tropicans · PM · suppurative myositis · tropical pyomyositis

Disease family

This is a subtype of bacterial myositis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › bacterial myositis › pyomyositis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03802552	PHASE1	COMPLETED	Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections
NCT03846804	Not specified	COMPLETED	Next-Generation Sequencing for Pathogen Detection and Quantification in Children With Musculoskeletal Infections

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CEPHALEXIN ANHYDROUS	4	3
CEFADROXIL	4	1
CHEMBL1555813	0	1